Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jason Butler
CJ
Jason Butler
Wall Street Analyst
★★☆☆☆
#2316
on 13Foresight · ranked by our own returns
50%
Success Rate
+4.9%
Average Return
17 of 34 calls profitable · -7.8% vs benchmark
📈 Across the calls we could measure, roughly 50% of Jason Butler's ratings turned a profit when each position was held for 1 year — averaging +4.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 1 Hold 0 Sell
Jason's Stock Coverage 40 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
ZVRA
Zevra Therapeutics
Jun 09, 2026 BUY Strong Buy
+85.5% avg upside
15 analysts
$25.00
93.77% Upside
-7.7%
RZLT
Rezolute
Jun 03, 2026 BUY Strong Buy
+122.3% avg upside
13 analysts
$11.00
119.13% Upside
·
ABVX
Abivax SA Sponsored ADR
Jun 02, 2026 BUY Strong Buy
+20.7% avg upside
15 analysts
$187.00
88.58% Upside
+38.1%
GHRS
GH Research
May 15, 2026 BUY Strong Buy
+64.5% avg upside
11 analysts
$39.00
75.28% Upside
+1.5%
PGEN
Precigen
May 14, 2026 BUY Buy
+404.8% avg upside
11 analysts
$11.00
128.17% Upside
+2.8%
AVTX
Avalo Therapeutics
May 14, 2026 BUY Strong Buy
+265.1% avg upside
19 analysts
$55.00
274.09% Upside
-14.0%
PRTA
Prothena
May 08, 2026 BUY Buy
+160.9% avg upside
14 analysts
$20.00
123.95% Upside
-20.9%
NERV
Minerva Neurosciences
Apr 15, 2026 BUY Buy
+68.3% avg upside
8 analysts
$14.00
213.30% Upside
-32.2%
NSRX
Nasus Pharma Ltd.
Mar 26, 2026 BUY Strong Buy
+551.5% avg upside
2 analysts
$18.00
486.39% Upside
·
ARGX
Argenx Se
Feb 27, 2026 BUY Strong Buy
-15.8% avg upside
46 analysts
$944.00
7.63% Upside
+15.1%
IRWD
Ironwood Pharma
Feb 26, 2026 BUY Hold
+235.8% avg upside
23 analysts
$10.00
182.49% Upside
-3.8%
ACAD
ACADIA Pharmaceuticals
Feb 26, 2026 BUY Strong Buy
+66.0% avg upside
42 analysts
$35.00
61.96% Upside
-12.3%
CYTK
Cytokinetics
Feb 25, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$96.00
21.93% Upside
+25.6%
ACHV
Achieve Life Sciences
Nov 25, 2025 BUY Strong Buy
+208.7% avg upside
12 analysts
$19.00
291.76% Upside
+16.8%
RAPP
Rapport Therapeutics, Inc.
Nov 07, 2025 BUY Strong Buy
+46.2% avg upside
12 analysts
$80.00
114.27% Upside
+43.7%
HALO
Halozyme
Nov 04, 2025 BUY Strong Buy
-13.7% avg upside
20 analysts
$92.00
34.15% Upside
+0.8%
AQST
Aquestive Therapeutics
Oct 09, 2025 BUY Strong Buy
+91.1% avg upside
10 analysts
$12.00
154.73% Upside
-35.6%
ESPR
Esperion
Sep 22, 2025 BUY Buy
+701.2% avg upside
22 analysts
$4.00
26.93% Upside
+25.5%
CRMD
Cormedix
Sep 09, 2025 BUY Strong Buy
+73.5% avg upside
13 analysts
$22.00
153.84% Upside
-34.5%
LONA
LeonaBio
May 12, 2025 HOLD Buy
+13.9% avg upside
9 analysts
+276.7%
VRDN
Viridian Therapeutics
May 07, 2025 BUY Strong Buy
+103.6% avg upside
32 analysts
$38.00
128.40% Upside
+38.3%
SYRS
Syros Pharmaceuticals
Dec 27, 2024 HOLD Buy
+10812400.0% avg upside
9 analysts
-99.6%
TRVN
Trevena
Dec 27, 2024 HOLD Buy
+128278.4% avg upside
11 analysts
·
FR:POXEL
Poxel SA
Nov 03, 2023 HOLD Hold
1 analyst
·
QNCX
Quince Therapeutics
Jun 09, 2023 HOLD Hold
+2771.2% avg upside
13 analysts
-50.0%
QNRX
Quoin Pharmaceuticals
Apr 06, 2023 HOLD Strong Buy
+661.3% avg upside
7 analysts
-85.5%
BXRXQ
Baudax Bio
Sep 03, 2021 HOLD Strong Buy
+18749999900.0% avg upside
3 analysts
·
OVID
Ovid Therapeutics
Aug 16, 2021 HOLD Strong Buy
+108.4% avg upside
17 analysts
-41.2%
GB:0QW0
arGEN X
Feb 01, 2021 BUY Strong Buy
-23.2% avg upside
24 analysts
$362.52
53.19% Downside
·
LEN
Lennar
Jan 09, 2020 BUY Hold
+7.5% avg upside
31 analysts
$70.00
21.91% Downside
+28.5%
LRMR
Larimar Therapeutics
Sep 05, 2019 HOLD Strong Buy
+413.5% avg upside
21 analysts
+45.8%
TARA
Protara Therapeutics
Mar 28, 2019 HOLD Strong Buy
+1153.9% avg upside
21 analysts
+9.3%
VNDA
Vanda
Feb 14, 2019 BUY Strong Buy
+253.1% avg upside
13 analysts
$52.00
796.56% Upside
-36.9%
MRVSY
Minerva SA
Oct 18, 2016 BUY Strong Buy
+200.8% avg upside
2 analysts
$17.00
423.12% Upside
·
EVR
Evercore Partners
Jul 28, 2016 BUY Buy
-31.4% avg upside
17 analysts
$61.00
83.63% Downside
+55.1%
MNKD
MannKind
May 10, 2016 HOLD Buy
+78.6% avg upside
22 analysts
-66.3%
VCEL
Vericel
Aug 16, 2013 BUY Strong Buy
+14.1% avg upside
16 analysts
$2.00
94.92% Downside
-44.0%
SLS
SELLAS Life Sciences Group
May 22, 2013 HOLD Strong Buy
+768.3% avg upside
15 analysts
-16.3%
DCTH
Delcath Systems
May 06, 2013 HOLD Strong Buy
+90.3% avg upside
11 analysts
·
TCRT
Alaunos Therapeutics
Mar 26, 2013 HOLD Buy
+603.1% avg upside
13 analysts
+169.8%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Jason Butler — Frequently Asked Questions
How accurate are Jason Butler's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Jason's ratings were profitable over a one-year hold, with an average return of +5.2% per rating, or -7.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Jason ranked on 13Foresight?
Jason Butler is currently ranked #2316 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jason cover?
Jason most recently has ratings on ZVRA, RZLT, ABVX, GHRS, PGEN, AVTX, PRTA, NERV, NSRX, ARGX, IRWD, ACAD and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.